SAN ANTONIO, TX--(Marketwired - February 05, 2014) - Targazyme, Inc. (formerly America Stem Cell, Inc.) has been selected to present at the 2014 BIO CEO & Investor Conference being held in New York City on February 10-11, 2014. The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded and select private biotech companies. Targazyme is a privately held clinical-stage biopharmaceutical company developing and commercializing breakthrough products designed to improve outcomes for patients receiving cell therapy. Targazyme will be presenting in the oncology track for private companies to some of the most influential members of the life science investment and biopharmaceutical communities.
"We are pleased to present the compelling interim clinical data from our current FDA study underway at MD Anderson for our most advanced product, TZ101," said Lynnet Koh, Targazyme's Founder and Chief Executive Officer. "TZ101 improves the therapeutic potential of cells by targeting their migration to the specific sites in the body where they are needed and improving their retention in those tissues. It is designed to increase the effectiveness of the therapeutic cells in stem cell transplantation, cancer immunotherapy and other therapeutic modalities. BIO CEO is the perfect forum to highlight our innovative platform to investors seeking novel and commercially meaningful approaches to address unmet medical needs."
About Targazyme, Inc.
Targazyme, Inc. is a privately held biotechnology company based in San Antonio, TX with additional offices in San Diego, CA and Basel, Switzerland. Its key technology platforms (TZ101 and TZ102) are designed to improve the homing and engraftment of a wide variety of therapeutic cells to target tissues. Applications in development include hematopoietic stem cell transplants, immunotherapies for solid tumors, cell therapies to ameliorate graft-versus-host and autoimmune diseases, and cell therapies for ischemic diseases such as myocardial infarction and stroke. Targazyme has partnerships and collaborations with Kyowa Hakko Kirin and Florida Biologix, as well as various medical research institutions including The University of Texas MD Anderson Cancer Center, Oklahoma Medical Research Foundation, Texas Transplant Institute, Case Western/University Hospitals, Scripps Hospitals, Fred Hutchinson Cancer Research Center, University of California San Diego, Sanford-Burnham Medical Research Institute and Indiana University. Learn more at http://www.targazyme.com.